Oak Hill Capital, a New York-based middle-market private equity firm, announced that it has partnered with Dan Renick to launch Petauri Health (Petauri), a purpose-built pharmaceutical commercialization services platform.
Petauri Health, based in New York, New York, will seek to acquire and combine best-in-class companies with recognized expertise in global market access, medical affairs, patient services, and data and analytics.
The resulting Petauri platform will strive to seamlessly support clients with data-driven, digital-forward solutions that speed patient access to life-changing care. Oak Hill aims to deploy in excess of $250 million of equity capital from its latest fund (OHCP VI) behind this initiative over time.
Petauri Health will work with pharmaceutical and life sciences clients to improve patient outcomes by establishing the scientific, economic, humanistic and societal value of medical advances.
Prior to forming Petauri Health, Dan Renick was a founding executive and President of Precision Value & Health following their acquisition of Hobart Group Holdings in 2013. Under his leadership, Precision Value & Health experienced outsized organic growth, completed numerous strategic acquisitions, and received multiple industry awards.
Across the commercialization continuum, Precision Value & Health teams are focused on transforming data for health and leveraging evidence and insights to tailor communications for every stakeholder. From payers to health systems, scientists to healthcare providers, and consumers to advocates, the company’s results are designed to shift the trajectory and accelerate client success.
Precision Value & Health’s teams include PRECISIONadvisors (global pricing and market access strategy), PRECISIONeffect (branding and launch experts), PRECISIONheor (evidence generation and strategy), PRECISIONscientia (medical communications), PRECISIONvalue (managed markets marketing), and PRECISIONxtract (data-driven solutions and engagement.
Takeaway: Petauri Health plans to partner with clients across numerous commercialization domains to overcome marketplace barriers and speed access to medical advances